

iModMix: Integrative Module Analysis for Multi-omics Data

Isis Narváez-Bandera¹ (Isis.Narvaez-Bandera@moffitt.org), Ashley Lui^{2,3} (Ashley.Lui@moffitt.org), Yonatan Ayalew Mekonnen² (YonatanAyalew.Mekonnen@moffitt.org), Vanessa Rubio² (Vanessa.Rubio@moffitt.org), Noah Sulman⁴ (Noah.Sulman@epi.usf.edu), Christopher Wilson¹ (cmwilson0109@gmail.com), Hayley D. Ackerman^{2,3} (Hayley.Ackerman@moffitt.org), Oscar E. Ospina¹ (Oscar.Ospina@moffitt.org), Guillermo Gonzalez-Calderon¹ (Guillermo.Gonzalez-Calderon@moffitt.org), Elsa Flores^{2,3} (Elsa.Flores@moffitt.org), Qian Li⁵ (qian.li@stjude.org), Ann Chen⁶ (Ann.Chen@hci.utah.edu), Brooke Fridley^{7*} (blfridley@cmh.edu), Paul Stewart^{1*} (Paul.Stewart@moffitt.org).

¹Department of Biostatistics and Bioinformatics, ²Department of Molecular Oncology, ³Cancer Biology and Evolution Program, Moffitt Cancer Center; ⁴Health Informatics Institute, University of South Florida; ⁵Department of Biostatistics, St. Jude Children's Research Hospital; ⁶Huntsman Cancer Institute, University of Utah; ⁷Division of Health Services and Outcome Research, Children's Mercy Research Institute, Kansas City.

*Corresponding Authors

Abstract

Summary: The integration of metabolomics with other omics ("multi-omics") offers complementary insights into disease biology. However, this integration remains challenging due to the fragmented landscape of current methodologies, which often require programming experience or bioinformatics expertise. Moreover, existing approaches are limited in their ability to accommodate unidentified metabolites, resulting in the exclusion of a significant portion of data from untargeted metabolomics experiments. Here, we introduce *iModMix*, a novel approach that uses a graphical lasso to construct network modules for integration and analysis of multi-omics data. *iModMix* uses a horizontal integration strategy, allowing metabolomics data to be analyzed alongside proteomics or transcriptomics to explore complex molecular associations within biological systems. Importantly, it can incorporate both annotated and unidentified metabolites, addressing a key limitation of existing methodologies. *iModMix* is available as a user-friendly R Shiny application that requires no programming experience (<https://imodmix.moffitt.org>), and it includes example data from several publicly available multi-omic studies for exploration. An R package is available for advanced users (<https://github.com/biodatalab/iModMix>).

Availability and implementation: Shiny application: <https://imodmix.moffitt.org>. The R package and source code: <https://github.com/biodatalab/iModMix>.

Introduction

Integration of metabolomics with other omics modalities, such as proteomics and transcriptomics, is essential for a comprehensive understanding of complex biological systems and disease mechanisms. The scale and complexity of these so-called "multi-omics" data necessitate computational approaches for effective integration and analysis. However, multi-omics analysis presents several challenges. These include the need for computational tools that are adaptable to diverse experimental setups and data types, as well as user-friendly enough to be used without extensive programming experience (Jendoubi 2021). Moreover, many approaches are unable to incorporate unidentified metabolites, resulting in the exclusion of large portions of data from untargeted metabolomics experiments, thereby limiting the potential for novel discoveries. Current pathway tools often restrict the inclusion of metabolite identifications due to naming mismatches and inconsistent use of standard identifiers like KEGG or HMDB IDs. This results in exclusion of some identified metabolites which cannot be fully utilized for analysis and further narrowing and hindering comprehensive insights (Jendoubi 2021).

In general, approaches for integrating metabolomics with other omics can be categorized into vertical or horizontal integration. Vertical integration takes multiple omics datasets as input and produces a single output, such as clustering assignments or a merged dataset, which no longer reflects the individual features of the original data. *iClusterPlus* (Q et al. 2013) is an example of vertical integration: it takes multiple omics datasets from the same samples as input, extracts latent factors across omics datasets, clusters samples in latent space, and outputs the clustering assignments by sample. In contrast, horizontal integration utilizes multiple omics datasets in parallel while maintaining the context of the original inputs. *PIUmet* (Benedetti et al. 2023) is an example of horizontal integration: it takes metabolomics and proteomics data as input, and the resulting network output contains both metabolites and proteins.

iModMix is a horizontal integration framework that constructs network modules from two input omics datasets (*e.g.*, metabolomics and proteomics, metabolomics and transcriptomics). It first uses graphical lasso to estimate a sparse Gaussian Graphical Model (GGM) (Friedman, Hastie, and Tibshirani 2008) for each input omics dataset. GGMs capture direct associations within the input omics datasets, which is an improvement over Weighted Gene Correlation Network Analysis (WGCNA) (Langfelder et al. 2008) module creation that includes both direct and indirect associations. Similar to WGCNA, a Topological Overlap Matrix (TOM) is next calculated (Yip et al. 2007), which quantifies the extent to which pairs of features share common neighbors. Hierarchical clustering is then performed on TOM dissimilarity ($1 - \text{TOM}$), using a dynamic tree cutoff to group related features into modules. *iModMix* next takes the first principal component of the abundances of the features in the module, called an eigenfeature (*e.g.*, eigenmetabolites for metabolomics, eigenproteins for proteomics). These eigenfeatures are representative of the contents of the module, and they can be used in place of normal metabolite abundance or protein expression for testing for differential expression or association with experimental conditions. Finally, integration between omics types is achieved by correlating the eigenfeatures from different omics experiments.

A major advantage of *iModMix* is its ability to generate network modules and their associated eigenfeatures independently of feature annotation. This allows *iModMix* to incorporate annotated and unidentified metabolites into its results. Since this method does not rely on existing pathway databases like KEGG, it can uncover new associations among features. *iModMix* is available as an R Shiny application (<https://imodmix.moffitt.org>) that provides an easy to use graphical interface and detailed documentation for users without programming expertise, and it is available as an R package (<https://github.com/biodatalab/iModMix>). *iModMix* can run on standard desktop computers with at least 8GB of RAM and a multi-core processor. The running time depends on the size and complexity of the dataset, but typical data sizes of 20,000 variables, the analysis can be completed in under an hour.

Implementation

Data Upload

The *iModMix* workflow accepts two omics datasets at a time (Fig. 1A). If available, users can provide feature-level annotation corresponding to the input omics dataset. A separate metadata file containing sample IDs and at least one sample grouping column (*e.g.*, treatment, control) are necessary for conducting PCA, heatmaps, and boxplots. Once uploaded, the tool scales the data by centering each feature to have a mean of zero and a standard deviation of one. Missing values are imputed using the k-nearest neighbors' algorithm, or users can also provide their own imputed data if a different method is preferred. We provide ten datasets encompassing gene expression and metabolomics data to illustrate *iModMix*'s capabilities. These datasets, from (Benedetti et al. 2023), have been formatted to meet *iModMix* specifications, with variable columns labeled as "Feature_ID" and sample columns labeled as "Samples". These datasets are designed to facilitate user engagement with *iModMix* and are readily accessible for download on Zenodo (<https://doi.org/10.5281/zenodo.13988161>). We also provide an in-house dataset of 20 lung adenocarcinoma mouse samples (10 wild type, 10 knockout), with 7353 metabolomics features and 7928 protein groups, to highlight *iModMix*'s functionality in handling unidentified metabolites.

Module Construction

iModMix first estimates partial correlations using the *glassoFast* R package (Friedman, Hastie, and Tibshirani 2008) (Fig. 1B) to build a GGM. Next, the TOM is computed and TOM dissimilarity ($1 - \text{TOM}$) is used for hierarchical clustering (Yip et al. 2007). Modules are created using the dynamic tree cut method, specifically the 'hybrid' method, which refines assignments derived from a static cut height by analyzing the shape of each branch (Langfelder, Zhang, and Horvath 2008). Finally, *iModMix* calculates eigenfeatures for each module using the *moduleEigengenes* function from the WGCNA R package (Langfelder et al. 2008) (Fig. 1B) that are used for downstream omics analyses.




Figure 1: Overview of iModMix. (A) iModMix integrates transcriptomics, proteomics, metabolomics, and clinical data to understand biological systems comprehensively. (B) Co-expression network: The tool performs independent analyses of each omics dataset to identify biologically relevant modules, and it then integrates the datasets by correlating eigenfeatures. (C) iModMix evaluates associations between phenotype-related modules across different data types. (D) Results of the integrated analysis of transcriptomics and metabolomics data from normal and tumor samples using iModMix. The network interaction and most correlated modules are also visualized.

Module Exploration

The phenotype analysis section provides a framework for classifying phenotypes based on eigenfeatures. Users can upload metadata, select phenotypes of interest, and set significance thresholds for statistical tests. The module performs classification using Student's t-test, comparing selected phenotypes and generating results that include t-statistics and p-values. Significant eigenfeatures are visualized through boxplots. Additionally, users can explore specific modules and view associated features, PCA loading, and heatmap plots to view feature behavior across different phenotypes (Fig. 1C). iModMix supports pathway enrichment analysis of genes or proteins by utilizing all available libraries in Enrichr (Kuleshov et al. 2016). This allows users to choose their preferred library, such as KEGG, GO, Human Gene Atlas, or WikiPathways.

Multi-omics analysis

iModMix integrates modules across omics datasets by calculating the Spearman correlation between eigenfeatures. *iModMix* then constructs an interactive network, where protein/gene modules are represented as green triangles and metabolite modules as yellow diamonds, with correlation coefficients shown on connecting arrows. Users can select the number of top multi-omics module correlations to visualize and explore detailed correlations within these modules through corrpplots and tables. Lists of metabolites and proteins/genes within highly correlated modules are provided, facilitating further pathway analysis and offering insights into the relationships between different omics layers. Additionally, classification between features of each layer and phenotypes using t-tests and boxplots is provided, enabling users to visualize and identify significant differences. (Fig. 1B).

Case-Study: ccRCC Dataset with Identified Metabolites

We used 24 normal and 52 tumor clear cell renal cell carcinoma (ccRCC) samples (Golkaram et al. 2022; Tang et al. 2023; Benedetti et al. 2023) as a case study. It contained 23001 genes from RNA-seq and 904 identified metabolites from untargeted metabolomics. Applying *iModMix* identified 401 gene modules and 24 metabolite modules. Differential expression analysis of the modules through t-test confirmed changes in metabolite abundance between groups recapitulated those from prior work (Benedetti et al. 2023) highlighting reduced levels of adenosine/C00212 (module ME#443A83FF, p-value = 0.0000), gamma-glutamyltyrosine (module ME#472D7BFF, p-value = 0.0001), creatinine/C00791 and 1-methyladenosine/C02494 (module ME#1F9A8AFF p-value = 0.0000) in tumors compared to normal tissue. Conversely, metabolites with increased abundance in tumors compared to normal tissues included fructose/C00095 (module ME#472D7BFF, p-value = 0.0001), proline/C00148 and glutamine/C00064 (module ME#35B779FF, p-value = 0.0023) (Benedetti et al. 2023). The top 5 correlated metabolomic modules to transcriptomic modules included pathways such as mitochondria fission and regulation of MAPK activity. Mitochondria fission results in lowered respiratory rates and emphasizes tumor reliance on glucose resulting in higher glycolysis rates common in renal cell carcinoma (Linehan et al. 2019).

Case-Study: Lung Adenocarcinoma Dataset with Unidentified Metabolites

Matched proteomics and metabolomics dataset was generated using two mouse models for lung adenocarcinoma (10 wild type, 10 knockout), with 7353 metabolomics features (annotated and unidentified) and 7928 protein groups. Applying *iModMix* generated 267 gene modules and 191 metabolite modules. High correlations were found between these modules, starting from a correlation threshold of 0.95. The second most correlated modules (protein module: ME#3ABA76FF with metabolite module: ME#238A8DFF), with a correlation of -0.94, included 14 genes (Gng11, Cnbp, Pkm, Aprt, Pfkfb3, Rbx1, Baz1b, Pgam1, Mif, Lgals3, Sp110, Map2, Mmrn2, Aldoc) and 21 metabolites, three of which are identified metabolites (Cortisol 21-acetate, Thymine, Deoxyuridine). Pathway analysis of these 14 genes and 3 metabolites using MetaboAnalyst (Pang et al. 2024) revealed significant enrichment in Glycolysis or Gluconeogenesis (P-value: 7.94E-7) and Pyrimidine metabolism (P-value: 0.0043961). Glycolysis and gluconeogenesis are known to be activated in non-small cell lung cancer (NSCLC) in a manner modulated by tumor size and oxygenation, and they differentially correlate with patient outcomes. The frequent co-activation of these pathways in NSCLC suggests their potential as targets for future therapeutic strategies aimed at cancer cell metabolism (Smolle et al. 2020). Additionally, high expression levels of pyrimidine metabolic rate-limiting enzymes have been identified as adverse prognostic factors in lung adenocarcinoma (LUAD). This reprogramming of metabolism is associated with clinical outcomes, indicating that the pyrimidine metabolism signaling pathway plays a significant role in LUAD prognosis (Wang et al. 2020).

Benchmarking

We benchmark *iModMix* to identify the optimal parameters for gene network construction using the *iModMix* algorithm. The process considers three input parameters: num_genes, num_fold, and lambda. Expression data from RC20 and lung adenocarcinoma mouse samples were used, and genes with the highest variance were selected,

constrained by `num_genes`. To identify the best sparsity parameter (λ), we applied five-fold cross-validation using the Graphical Lasso (Glasso) algorithm, which calculates a sparse Gaussian Graphical Model (GGM) for each input omics dataset. The Glasso model was fitted using the `glassoFast` function with λ , and metrics such as the number of non-zero partial correlations, log-likelihood, and execution time were evaluated. Hierarchical clustering analysis was then used to identify gene modules. Stability was achieved in both datasets with an alpha value of 0.25 (Fig. S1A, Fig. S1B), allowing for efficient and accurate model evaluation across various configurations. This benchmarking process demonstrates that *iModMix* offers a refined approach to network construction by focusing on direct associations, making it a robust alternative to WGCNA for complex omics data.

Summary:

The *iModMix* pipeline captures interactions that could not be observable with metabolomics or transcriptomics alone. *iModMix* progresses the field of multi-omic analysis with advantages such as *de novo* network generation, independent of existing pathway databases and the ability to integrate annotated and unidentified metabolites for multi-omic analysis.

Acknowledgments

Funding: This work was supported in part by:

- The Biostatistics and Bioinformatics Shared Resource and the Proteomics and Metabolomics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292)
- The Cancer Research Institute (Stewart)
- P01CA250984, 'Identifying Metabolic Vulnerabilities in Lung Cancer,'
- [T32 CA233399/CA/NCI NIH HHS/United States](#)
- The Anna D. Valentine and Charles L. Oehler Award (Li/Fridley/Chen) funded prior work.


References

- Benedetti, E., EM. Liu, C. Tang, F. Kuo, M. Buyukozkan, T. Park, J. Park, F. Correa, AA. Hakimi, AM. Intlekofer, J. Krumsiek, and E. Reznik. 2023. 'A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation', *Nature metabolism*, 5.
- Friedman, Jerome, Trevor Hastie, and Robert Tibshirani. 2008. 'Sparse inverse covariance estimation with the graphical lasso', *Biostatistics*, 9.
- Golkaram, Mahdi, Fengshen Kuo, Sounak Gupta, Maria I. Carlo, Michael L. Salmans, Raakhee Vijayaraghavan, Cerise Tang, Vlad Makarov, Phillip Rappold, Kyle A. Blum, Chen Zhao, Rami Mehio, Shile Zhang, Jim Godsey, Traci Pawlowski, Renzo G. DiNatale, Luc G. T. Morris, Jeremy Durack, Paul Russo, Ritesh R. Kotecha, Jonathan Coleman, Ying-Bei Chen, Victor E. Reuter, Robert J. Motzer, Martin H. Voss, Li Liu, Ed Reznik, Timothy A. Chan, A. Ari Hakimi, Mahdi Golkaram, Fengshen Kuo, Sounak Gupta, Maria I. Carlo, Michael L. Salmans, Raakhee Vijayaraghavan, Cerise Tang, Vlad Makarov, Phillip Rappold, Kyle A. Blum, Chen Zhao, Rami Mehio, Shile Zhang, Jim Godsey, Traci Pawlowski, Renzo G. DiNatale, Luc G. T. Morris, Jeremy Durack, Paul Russo, Ritesh R. Kotecha, Jonathan Coleman, Ying-Bei Chen, Victor E. Reuter, Robert J. Motzer, Martin H. Voss, Li Liu, Ed Reznik, Timothy A. Chan, and A. Ari Hakimi. 2022. 'Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape', *Genome Medicine* 2022 14:1, 14.
- Jendoubi, Takoua. 2021. 'Approaches to Integrating Metabolomics and Multi-Omics Data: A Primer', *Metabolites* 2021, Vol. 11, Page 184, 11.
- Kuleshov, Maxim V., Matthew R. Jones, Andrew D. Rouillard, Nicolas F. Fernandez, Qiaonan Duan, Zichen Wang, Simon Koplev, Sherry L. Jenkins, Kathleen M. Jagodnik, Alexander Lachmann, Michael G. McDermott, Caroline D. Monteiro, Gregory W. Gundersen, and Avi Ma'ayan. 2016. 'Enrichr: a comprehensive gene set enrichment analysis web server 2016 update', *Nucleic Acids Research*, 44.
- Langfelder, Peter, Steve Horvath, Peter Langfelder, and Steve Horvath. 2008. 'WGCNA: an R package for weighted correlation network analysis', *BMC Bioinformatics* 2008 9:1, 9.

- Langfelder, Peter, Bin Zhang, and Steve Horvath. 2008. 'Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R', *Bioinformatics*, 24.
- Linehan, W. Marston, Christopher J. Ricketts, W. Marston Linehan, and Christopher J. Ricketts. 2019. 'The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications', *Nature Reviews Urology* 2019 16:9, 16.
- Pang, Zhiqiang, Lei Xu, Charles Viau, Yao Lu, Reza Salavati, Niladri Basu, Jianguo Xia, Zhiqiang Pang, Lei Xu, Charles Viau, Yao Lu, Reza Salavati, Niladri Basu, and Jianguo Xia. 2024. 'MetaboAnalystR 4.0: a unified LC-MS workflow for global metabolomics', *Nature Communications* 2024 15:1, 15.
- Q, Mo, Wang S, Seshan VE, Olshen AB, Schultz N, Sander C, Powers RS, Ladanyi M, and Shen R. 2013. 'Pattern discovery and cancer gene identification in integrated cancer genomic data - PubMed', *Proceedings of the National Academy of Sciences of the United States of America*, 110.
- Smolle, Elisabeth, Petra Leko, Elvira Stacher-Priehse, Luka Brcic, Amin El-Heliebi, Lilli Hofmann, Franz Quehenberger, Andelko Hrzenjak, Helmut H. Popper, Horst Olschewski, and Katharina Leithner. 2020. 'Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer', *Molecular Oncology*, 14.
- Tang, Cerise, Amy X Xie, Minwei Liu, Fengshen Kuo, Minsoo Kim, Renzo Di Natale, Mahdi Golkaram, Yingbei Chen, Sounak Gupta, Robert Motzer, Paul Russo, Jonathan Coleman, Maria I Carlo, Martin H Voss, Ritesh R Kotecha, Chung Han Lee, Wesley Tansey, Nikolaus Schultz, A Ari Hakimi, and Ed Reznik. 2023. 'Immunometabolic coevolution defines unique microenvironmental niches in ccRCC', *Cell metabolism*, 35.
- Wang, Haiwei, Xinrui Wang, Liangpu Xu, Ji Zhang, Hua Cao, Haiwei Wang, Xinrui Wang, Liangpu Xu, Ji Zhang, and Hua Cao. 2020. 'High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets', *Purinergic Signalling*, 16.
- Yip, Andy M, Steve Horvath, Andy M Yip, and Steve Horvath. 2007. 'Gene network interconnectedness and the generalized topological overlap measure', *BMC Bioinformatics* 2007 8:1, 8.

Supplementary Figure 1. Benchmarking results.

Metabolomic abundance RC20 data



Gene expression data lung adenocarcinoma mouse samples data

